구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pneumococcal Conjugate Vaccine, Heptavalent (Pneumococcal Conjugate Vaccine, Heptavalent) Sanofi Pasteur, a Sanofi Company·HIV Infections 52 trials·t½ 12 h |
|---|---|
Overview Program | Pneumococcal Conjugate Vaccine, Heptavalent |
Overview Company | Sanofi Pasteur, a Sanofi Company |
Overview Modality | ADC |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Half-life | 12 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).. Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate… |
Clinical Safety signal | A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).. Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate… |
Clinical Selected reported efficacy | 1% |
Clinical Result source | ClinicalTrials.gov NCT01307449 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT01307449 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pneumococcal Conjugate Vaccine, Heptavalent (Pneumococcal Conjugate Vaccine, Heptavalent) Sanofi Pasteur, a Sanofi Company·HIV Infections 52 trials·t½ 12 h |
|---|---|
Overview Program | Pneumococcal Conjugate Vaccine, Heptavalent |
Overview Company | Sanofi Pasteur, a Sanofi Company |
Overview Modality | ADC |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Half-life | 12 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).. Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate… |
Clinical Safety signal | A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).. Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate… |
Clinical Selected reported efficacy | 1% |
Clinical Result source | ClinicalTrials.gov NCT01307449 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT01307449 |
추천 비교
추천 비교